{"id":2355,"date":"2025-01-08T17:41:32","date_gmt":"2025-01-08T14:41:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2355"},"modified":"2025-03-07T15:26:36","modified_gmt":"2025-03-07T12:26:36","slug":"avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization\/","title":{"rendered":"Avidity Biosciences, \u00dc\u00e7 Nadir Kas Hastal\u0131\u011f\u0131 Program\u0131n\u0131n 2025 BLA Ba\u015fvurusu ve Ticarile\u015ftirilmesine Haz\u0131rlan\u0131yor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Antikor Oligon\u00fckleotid Konjugatlar\u0131 (AOCsTM) olarak bilinen yeni bir RNA tedavi s\u0131n\u0131f\u0131 geli\u015ftirmeye adanm\u0131\u015f bir biyofarmas\u00f6tik firmas\u0131 olan Avidity Biosciences, Inc., bug\u00fcn 2025&#039;te oyunun kurallar\u0131n\u0131 de\u011fi\u015ftirecek bir y\u0131l i\u00e7in geli\u015fmelerini ve planlar\u0131n\u0131 duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00f6nemli beklenen kilometre ta\u015flar\u0131 aras\u0131nda, potansiyel olarak kay\u0131t alt\u0131na al\u0131nabilecek \u00fc\u00e7 program\u0131n tamamlanmas\u0131, ekzon 44 atlamaya uygun Duchenne kas distrofisi mutasyonlar\u0131 (DMD44) olan bireyler i\u00e7in delpacibart zotadirsen (del-zota) i\u00e7in Biyolojik Lisans Ba\u015fvurusu&#039;nun (BLA) sunulmas\u0131, DMD44, miyotonik distrofi tip 1 (DM1) ve fasioskapulohumeral kas distrofisi (FSHD) alanlar\u0131nda \u00e7e\u015fitli \u00fcr\u00fcn lansmanlar\u0131na haz\u0131rlanma ve hassas kardiyoloji ve n\u00f6rom\u00fcsk\u00fcler hastal\u0131klar alan\u0131nda geni\u015fleyen bir AOC hatt\u0131n\u0131 desteklemek \u00fczere tamamen entegre, uluslararas\u0131 bir i\u015fletmenin kurulmas\u0131 yer al\u0131yor.<\/p>","protected":false},"excerpt":{"rendered":"<p>A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[126,128,130,129,66,77],"class_list":["post-2355","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-avidity-biosciences","tag-bla","tag-dm1","tag-dmd44","tag-duchenne-muscular-dystrophy","tag-exon-skipping"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=2355"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2355\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/2357"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=2355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=2355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=2355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}